AspenBio Pharma | Animal Health

AspenBio Pharma Investor Relations

Investor Relations

AspenBio Pharma, Inc. Animal Health (AAH) division employs conventional biotechnology to develop innovative tools for reproduction management of cattle, swine, horses and other species. We are focused on product concepts utilizing reproductive physiology and molecular endocrinology. These concepts are being developed into therapeutic products using our patented platform that enables specific modulation of natural physiological processes.

For additional information please review our most recent 10K or 10Q available at SEC.gov or click on:

Company Presentation

Recent Press Releases

<back / top

Certain statements made in this presentation include historical information and forward looking actions that AspenBio Pharma anticipates based on certain assumptions. These statements are indicated by words such as “expect”, “anticipate”, “should” and similar words are indicating uncertainty in facts, figures and outcomes. While AspenBio Pharma believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such statements will prove to be correct. The risks associated with the company are detailed in the Company’s Annual Report, as amended on Form 10-K for the year ended December 31, 2010 and other reports filed by the Company with the Securities and Exchange Commission.

Solutionsin Reproduction & Fertility

Investor Relations

Solutions
in Reproduction & Fertility